InsidersTradesSigma
Pear Therapeutics, Inc. Stock: price and directors' dealings · United States · SEC (Form 4)
Track the Pear Therapeutics, Inc. stock price and the full management transaction log of the company, a listed equity based in United States. Shares are quoted on US US, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, Pear Therapeutics, Inc. has logged 46 public disclosures. The latest transaction was filed on 12 April 2023 (Cession). Among the most active insiders: 5AM Partners IV, LLC. Every trade is accessible without an account.
46
Insider Decl.
0
Thresholds
·
0 ops.
Buy Volume
€3m
19 ops.
Sell Volume
48Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 12 April 2023
Declarations46 total
12,836,489 shares@ US$0.1242.5% of flowClass A Common StockSEC:0001209191-23-024105:0
52,380 shares0Class A Common StockSEC:0001062993-23-004031:0
66,666 shares0Class A Common StockSEC:0001062993-23-004036:0
71,428 shares0Class A Common StockSEC:0001062993-23-004029:0
61,904 shares0Class A Common StockSEC:0001062993-23-004034:0
52,380 shares0Class A Common StockSEC:0001062993-23-004032:0
52,380 shares0Class A Common StockSEC:0001062993-23-004037:0
8,027 shares@ US$1.13100.0% of flowClass A Common StockSEC:0001062993-23-001326:0
34,731 shares@ US$1.13100.0% of flowClass A Common StockSEC:0001062993-23-001323:0
12,162 shares@ US$1.13100.0% of flowClass A Common StockSEC:0001062993-23-001324:0
19,540 shares@ US$1.13100.0% of flowClass A Common StockSEC:0001062993-23-001325:0
12,688 shares@ US$1.13100.0% of flowClass A Common StockSEC:0001062993-23-001328:0
7,096 shares@ US$1.13100.0% of flowClass A Common StockSEC:0001062993-23-001321:0
8,690 shares@ US$1.1324.3% of flowClass A Common StockSEC:0001062993-23-001327:0
12,162 shares@ US$1.13100.0% of flowClass A Common StockSEC:0001062993-23-001329:0
30,800 shares0Common StockSEC:0001062993-23-001040:0
33,000 shares0Common StockSEC:0001062993-23-001036:0
49,500 shares0Common StockSEC:0001062993-23-001038:0
30,800 shares0Common StockSEC:0001062993-23-001035:0
15,400 shares0Common StockSEC:0001062993-23-001034:0
22,000 shares0Common StockSEC:0001062993-23-001046:0
88,000 shares0Common StockSEC:0001062993-23-001039:0
20,320 shares0Common StockSEC:0001062993-23-001037:0
15,000 shares@ US$1.0038.1% of flowCommon StockSEC:0001062993-22-023633:0
25 of 46 declarations
About Pear Therapeutics, Inc.
Pear Therapeutics, Inc. was a U.S.-based digital health company focused on prescription digital therapeutics, or software-based treatments designed to complement or, in some cases, replace parts of traditional care pathways. The company was listed on the U.S. NASDAQ market under the ticker PEAR, and it was headquartered in Boston, Massachusetts, United States. Boston was a logical base for the business given its proximity to the life sciences, biotech, and healthcare innovation ecosystem. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1835567/000183556723000018/pear-20221231.htm?utm_source=openai)) Pear emerged as one of the early pioneers in prescription digital therapeutics, building its investment case around FDA-authorized software therapies. That regulatory moat mattered because the category was still relatively new, clinically specialized, and reimbursement-sensitive. In December 2021, the post-business-combination company began trading on the Nasdaq Capital Market under the PEAR symbol. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1835567/000183556722000041/pear_2022investordaypres.htm?utm_source=openai)) The company’s commercial portfolio centered on three FDA-authorized products. reSET was designed for substance use disorder, reSET-O targeted opioid use disorder in combination with buprenorphine, and Somryst addressed chronic insomnia. Pear marketed these products alongside PearMD, a clinician-facing dashboard intended to support monitoring, engagement, and integration into care delivery. From a competitive standpoint, Pear positioned itself as a category creator and first mover, with some of the earliest FDA-authorized PDTs in the market. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1835567/000183556723000018/pear-20221231.htm?utm_source=openai)) Geographically, Pear was primarily a U.S. commercial story. Its core commercialization efforts were concentrated in the United States, although its filings also referenced limited international reach, including authorization for reSET in Singapore. The company relied on access agreements with health systems, payers, state agencies, and other healthcare stakeholders, while continuing to navigate the broader challenge of payer coverage, physician adoption, and patient utilization that typically shapes the economics of digital therapeutics. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1835567/000183556723000018/pear-20221231.htm?utm_source=openai)) The most important recent development was highly material and negative for equity investors: on April 7, 2023, Pear announced that it had filed for Chapter 11 bankruptcy protection in the United States with the intention to sell its assets. Before that filing, the company had already withdrawn revenue and operating guidance and initiated a strategic review aimed at maximizing shareholder value. In practical terms, that means PEAR should be viewed through a restructuring lens rather than as a normal operating growth equity. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1835567/000183556723000020/peartherapeuticsfilesforch.htm?utm_source=openai))
